{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:11:59Z","timestamp":1790766719692,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supplement 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:sec>\n            <jats:title>Goals:<\/jats:title>\n            <jats:p>The aim of the study was to unequivocally demonstrate the nontransmissibility of the genes mediating the resistance of the strain <jats:italic toggle=\"yes\">Bifidobacterium longum<\/jats:italic> W11 (LMG P-21586) to rifaximin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Most antibiotic treatments can induce unfavorable side effects such as antibiotic-associated diarrhea, which is largely attributable to the disruption of the intestinal microbiota. The parallel intake of probiotic bacteria might reduce these events, even if with generally very poor results. In this regard, the use of antibiotic-resistant beneficial bacteria could represent a worthy strategy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Study:<\/jats:title>\n            <jats:p>Rifaximin was tested in parallel with rifampicin, rifapentine, and rifabutin, all rifamycin derivates, using 5 different concentrations. Susceptibility tests were performed by the disc diffusion method of Kirby-Bauer, and inhibition zones were measured after incubation at 37\u00b0C. <jats:italic toggle=\"yes\">B. longum<\/jats:italic> BL03 was used as comparison. The <jats:italic toggle=\"yes\">B. longum<\/jats:italic> W11 genome was sequenced on Illumina MiSeq with a 250 PE reads module. After mapping the reads with the reference bacterial genome, the alignment data were processed using FreeBayes software.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>\n                                 <jats:italic toggle=\"yes\">B. longum<\/jats:italic> BL03 was inhibited by all antibiotics even at the lowest concentration. In contrast, the W11 strain was inhibited by rifampicin, rifabutin, and rifaximin only at the highest concentration (512 \u03bcg\/mL). The genomic analysis showed a mutation into the chromosomal DNA. No transposable elements were found, and the genetic locus was not flanked by close mobile genetic elements.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>\n                                 <jats:italic toggle=\"yes\">B. longum<\/jats:italic> W11 could be used in combined therapy with rifaximin, thus opening new focused frontiers in the probiotic era while preserving the necessary safety of use for consumers.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mcg.0000000000000683","type":"journal-article","created":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T11:18:08Z","timestamp":1476357488000},"page":"S153-S156","source":"Crossref","is-referenced-by-count":15,"title":["The Possible Innovative Use of Bifidobacterium longum W11 in Association With Rifaximin"],"prefix":"10.1097","volume":"50","author":[{"given":"Teresa","family":"Graziano","sequence":"first","affiliation":[{"name":"Biolab Research Ltd, Novara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Amoruso","sequence":"additional","affiliation":[{"name":"Biolab Research Ltd, Novara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Nicola","sequence":"additional","affiliation":[{"name":"Biolab Research Ltd, Novara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Deidda","sequence":"additional","affiliation":[{"name":"Biolab Research Ltd, Novara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Allesina","sequence":"additional","affiliation":[{"name":"Biolab Research Ltd, Novara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pane","sequence":"additional","affiliation":[{"name":"Biolab Research Ltd, Novara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Piffanelli","sequence":"additional","affiliation":[{"name":"PTP Science Park, Lodi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Strozzi","sequence":"additional","affiliation":[{"name":"PTP Science Park, Lodi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mogna","sequence":"additional","affiliation":[{"name":"Biolab Research Ltd, Novara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Del Piano","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Santa Rita Hospital\u2014Policlinico di Monza, Vercelli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-20230913","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/ajcn\/73.2.393s","article-title":"Quality assurance criteria for probiotic bacteria","volume":"73","author":"Tuomola","year":"2001","journal-title":"Am J Clin Nutr"},{"key":"R4-20230913","first-page":"2740","article-title":"Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance","volume":"10","year":"2012","journal-title":"EFSA Journal"},{"key":"R5-20230913","doi-asserted-by":"crossref","first-page":"14422","DOI":"10.1073\/pnas.212527599","article-title":"The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract","volume":"99","author":"Schell","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6-20230913","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2249.2007.03522.x","article-title":"Differential immunomodulatory properties of Bifidobacterium longum strains: relevance to probiotic selection and clinical applications","volume":"150","author":"Medina","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"R7-20230913","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1472-765X.2006.02031.x","article-title":"Factors involved in binding of Lactobacillus plantarum Lp6 to rat small intestinal mucus","volume":"44","author":"Sun","year":"2007","journal-title":"Lett Appl Microbiol"},{"key":"R8-20230913","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0958-6946(01)00160-1","article-title":"An overview of the functionality of exopolysaccharides produced by lactic acid bacteria","volume":"12","author":"Ruas-Madiedo","year":"2002","journal-title":"Int Dairy J"},{"key":"R9-20230913","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00203-015-1141-0","article-title":"Impact of exopolysaccharide production on functional properties of some Lactobacillus salivarius strains","volume":"197","author":"Mercan","year":"2015","journal-title":"Arch Microbiol"},{"key":"R10-20230913","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1073\/pnas.1115621109","article-title":"Bifidobacterial surface-exopolisaccharide facilitates commensal-host interaction through immune modulation and pathogen protection","volume":"109","author":"Fanning","year":"2012","journal-title":"PNAS"},{"key":"R11-20230913","first-page":"1787","article-title":"Scanning electron microscopy observation of adhesion properties of Bifidobacterium longum W11 and chromatographic analysis of its exopolysaccaride","volume":"5","author":"Inturri","year":"2014","journal-title":"Food Nutr Sci"},{"key":"R12-20230913","first-page":"149","article-title":"Adhesion properties of Bifidobacterium pseudocalenulatum G4 and Bifidobacterium longum BB 536 on HT29 human epithelial cell line and different times and pH","volume":"49","author":"Ali","year":"2009","journal-title":"World Acad Sci Eng Technol"},{"key":"R13-20230913","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003495-199549030-00009","article-title":"Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria","volume":"49","author":"Gillis","year":"1995","journal-title":"Drugs"},{"key":"R14-20230913","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000081990","article-title":"Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential","volume":"51","author":"Scarpignato","year":"2005","journal-title":"Chemotherapy"},{"key":"R15-20230913","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2165\/00003495-200565120-00011","article-title":"Rifaximin: a review of its use in the management of traveller\u2019s diarrhoea","volume":"65","author":"Robins","year":"2005","journal-title":"Drugs"},{"key":"R16-20230913","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000081997","article-title":"Management of diverticular disease: is there room for rifaximin","volume":"51","author":"Papi","year":"2005","journal-title":"Chemotherapy"},{"key":"R17-20230913","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1046\/j.1365-2036.2000.00751.x","article-title":"Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth","volume":"14","author":"Di Stefano","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R18-20230913","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1185\/030079905X53252","article-title":"An open-label evaluation of rifaximin in the treatment of active Crohn\u2019s disease","volume":"21","author":"Shafran","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"R19-20230913","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0016-5085(00)85267-1","article-title":"Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn\u2019s disease: a randomized controlled study versus mesalazine","volume":"118","author":"Campieri","year":"2000","journal-title":"Gastroenterology"},{"key":"R20-20230913","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2174\/138161209788168173","article-title":"The role of gut microbiota in drug response","volume":"15","author":"Wilson","year":"2009","journal-title":"Curr Pharm Des"},{"key":"R21-20230913","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijantimicag.2009.11.013","article-title":"Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei","volume":"35","author":"Jiang","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"R22-20230913","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1128\/AAC.00691-09","article-title":"Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles","volume":"54","author":"Brown","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-20230913","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/00365520802321204","article-title":"Involvement of central immunity in uncomplicated diverticular disease","volume":"44","author":"Cianci","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"R24-20230913","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ijantimicag.2008.10.007","article-title":"Immunoregolatory activity of rifaximin associated with a resistant mutant of Bifidobacterium infantis","volume":"33","author":"Vitali","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"R25-20230913","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1093\/jac\/dkq345","article-title":"Rifaximin modulates the colonic microbiota of patients with Crohn\u2019s disease: an in vitro approach using a continuous culture colonic model system","volume":"65","author":"Maccaferri","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R26-20230913","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tim.2016.02.001","article-title":"Involvement of bacteria other than Clostridium difficile in antibiotic-associated diarrhoea","volume":"24","author":"Larcombe","year":"2016","journal-title":"Trends Microbiol"},{"key":"R27-20230913","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1099\/jmm.0.028571-0","article-title":"Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile","volume":"60","author":"Huhulescu","year":"2011","journal-title":"J Med Microbiol"},{"key":"R28-20230913","first-page":"135","article-title":"Antimicrobial susceptibility testing by the Kirby-Bauer disc diffusion method","volume":"3","author":"Biemer","year":"1973","journal-title":"Ann Clin Lab Sci"},{"key":"R29-20230913","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly (Austin)"},{"key":"R30-20230913","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1128\/AAC.43.11.2813","article-title":"Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus","volume":"43","author":"Wichelhaus","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-20230913","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/AAC.02163-12","article-title":"Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-\u03b2-naphthylamide-inhibitable efflux pumps","volume":"57","author":"Kothary","year":"2013","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00004836-201611001-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T21:17:25Z","timestamp":1694639845000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004836-201611001-00013"}},"subtitle":["A New Horizon for Combined Approach?"],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":29,"journal-issue":{"issue":"Supplement 2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0000000000000683","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}